Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pico-Tesla plans atrial fibrillation trial

This article was originally published in The Gray Sheet

Executive Summary

Pico-Tesla will begin a U.S. clinical trial of its Resonator electromagnetic field generator to treat paroxysmal atrial fibrillation in the fourth quarter, according to the company. Clinical trials are already ongoing for use of the device to create low-level electromagnetic fields (EMF) to treat Parkinson's disease and type-2 diabetes. In May, a dog study at the University of Oklahoma's Heart Rhythm Institute suggested EMF fields from the device can terminate and prevent atrial fibrillation. The so-called Magneceutical therapy system comprises two large magnetic coils; patients sit between the coils for treatment (1"The Gray Sheet" Nov. 9, 2009)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel